This site is intended for healthcare professionals
Drug news

FDA advisory committee recommends Probuphine to treat opioid dependence- Titan Pharmaceuticals

Read time: 1 mins
Last updated:14th Jan 2016
Published:14th Jan 2016
Source: Pharmawand

The Psychopharmacologic Drugs Advisory Committee (PDAC) of the FDA voted 12 to 5 in favour of approving Probuphine, from Titan Pharmaceuticals, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8 mg or less per day of buprenorphine. The Committee's vote followed presentation and discussion of data regarding Probuphine's efficacy, safety, and risk-benefit profile.

The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015. A target agency action date has been set for 27 February 2016.

Comment: Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, and to promote patient compliance and retention. Buprenorphine, which is the active ingredient in multiple FDA-approved drug products for the treatment of opioid addiction, is currently available in tablet and film formulations that require self-administration by patients on a daily basis.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.